Market Research Report
Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027
|Published by||DelveInsight Business Research LLP||Product code||602082|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027|
|Published: December 1, 2018||Content info: 100 Pages||
DelveInsight's ‘Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Major Depressive Disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Major Depressive Disorder (MDD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2016-2027
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called Major Depressive Disorder or clinical depression, it affects how patient feel, think and behave and can lead to a variety of emotional and physical problems.
The exact cause of Major Depressive Disorder (MDD) isn't known. However, there are several factors that can increase the risk of developing the condition. A combination of genes and stress can affect brain chemistry and reduce the ability to maintain mood stability. Changes in the balance of hormones might also contribute to the development of Major Depressive Disorder (MDD).
Symptoms of Major Depressive Disorder (MDD) may include-Feelings of sadness, tearfulness, hopelessness, Sleep disturbances, including insomnia or sleeping too much, Anxiety, agitation or restlessness etc.
The DelveInsight Major Depressive Disorder (MDD) market report gives the thorough understanding of the Major Depressive Disorder (MDD) by including details such as disease definition, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Major Depressive Disorder (MDD) in the US, Europe, and Japan.
The Major Depressive Disorder (MDD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalent population of Major Depressive Disorder (MDD), Gender specific Prevalent of Major Depressive Disorder (MDD), Diagnosed and treatable Cases of Major Depressive Disorder (MDD)] scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
As per Anxiety and Depression Association of America (ADAA), the leading cause of MDD disability in the U.S. for ages 15 to 44.3.MDD affects about 6.7%of the U.S. population age 18 and older in a given year. While Major Depressive Disorder can develop at any age, the median age at onset is 32.5 years old. More prevalent in women than in men.
According to National Institute of Mental Health (NIMH), the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%). Major depression is one of the most common mental disorders in the United Stat. In 2016, an estimated 10.3 million U.S. adults aged 18 or older had at least one major depressive episode with severe impairment. This number represented 4.3% of all U.S. adults. The prevalence of major depressive episode was higher among adult females (8.5%) compared to males (4.8%). The prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%).
DelveInsight estimates that the prevalent population of Major Depressive Disorder (MDD) will significantly change during the study period [2016-2027].
This segment of the Major Depressive Disorder (MDD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently treatment of Major Depressive Disorder (MDD) include -Antidepressant medications (Selective serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants and atypical antidepressants).
Additionally, there are some FDA approved therapies for the treatment of Major Depressive Disorder (MDD) which include-Aripiprazole (BristolMyers Squibb), Aplenzin (Valeant Pharmaceuticals), Emsam (Somerset pharmaceuticals)
Key players such as Fabre-Kramer Pharmaceuticals, Sage Therapeutics and many others are involved in developing therapies for Major Depressive Disorder (MDD). Expected launch of emerging therapies such as Travivo (Fabre-Kramer Pharmaceuticals), SAGE-217 (Sage Therapeutics) and some other are expected to change the treatment landscape of Major Depressive Disorder (MDD) in upcoming years.
The Major Depressive Disorder (MDD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Major Depressive Disorder (MDD) in 7MM is expected to increase from 2016-2027.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
To be continued in the report…
To be continued in report…